• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

    Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

  2. Innovation, not easy money, is behind the Nasdaq's return to 5,000

    Innovation, not easy money, is behind the Nasdaq's return to 5,000

  3. Research and Markets: Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

    Research and Markets: Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

  4. Research and Markets: Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles

    Research and Markets: Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles

  5. Ultimate Stock-Pickers' Top 10 High-Conviction Purchases

    These top investment managers put new money to work in several wide-moat names, including United Technologies.

  6. UPDATE: CVS girds for battle over cholesterol drugs

    UPDATE: CVS girds for battle over cholesterol drugs

  7. CVS girds for battle over cholesterol drugs

    CVS girds for battle over cholesterol drugs

  8. Daniel Loeb's Third Point boosts stock holdings, adding new stakes in Citigroup and Delta

    Daniel Loeb's Third Point boosts stock holdings, adding new stakes in Citigroup and Delta

  9. Research and Markets: Global Erythropoietin Drugs Market (Products, Applications and Geography) - Size, Global Trends, Company Profiles, Segmentation and Forecast, 2013 - 2020

    Research and Markets: Global Erythropoietin Drugs Market (Products, Applications and Geography) - Size, Global Trends, Company Profiles, Segmentation and Forecast, 2013 - 2020

  10. Compugen Expands and Strengthens Business Development Team

    Compugen Expands and Strengthens Business Development Team

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.